Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Ischemic Heart Disease

Free Subscription Articles published in Am Heart J Retrieve available abstracts of 180 articles: HTML format Text format

Single Articles

May 2019
1. 
   Correction to "Sex differences in long-term outcomes of patients across the spectrum of coronary artery disease", [American Heart Journal (December 2018) 51-60].
   Am Heart J. 2019 May 29. pii: S0002-8703(19)30112.
   PubMed     Text format    
   
   
   
2. PUYMIRAT E, Cayla G, Cottin Y, Elbaz M, et al
   Twenty-year trends in profile, management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: Data from the FAST-MI program 1995-2015.
   Am Heart J. 2019;214:97-106.
   PubMed     Text format     Abstract available
   
   
   
3. TOTH G, Brodmann M, Barbato E, Mangiacapra F, et al
   Rational and design of the INtentional COronary revascularization versus conservative therapy in patients undergOing successful peripheRAl arTEry revascularization due to critical limb ischemia trial (INCORPORATE trial).
   Am Heart J. 2019;214:107-112.
   PubMed     Text format     Abstract available
   
   
   
4. MENTIAS A, Shantha G, Adeola O, Barnes GD, et al
   Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis.
   Am Heart J. 2019;214:158-166.
   PubMed     Text format     Abstract available
   
   
   
5. GAZIANO TA, Pandya A, Sy S, Jardim TV, et al
   Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
   Am Heart J. 2019;214:77-87.
   PubMed     Text format     Abstract available
   
   
   
6. GELMAN A, Carlin JB, Nallamothu BK
   Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) and coronary stents: A case study in the analysis and reporting of clinical trials.
   Am Heart J. 2019;214:54-59.
   PubMed     Text format    
   
   
   
7. DOUCET S, Jolicoeur EM, Serruys PW, Ragosta M 3rd, et al
   Outcomes of left main revascularization in patients with acute coronary syndromes and stable ischemic heart disease: Analysis from the EXCEL trial.
   Am Heart J. 2019;214:9-17.
   PubMed     Text format     Abstract available
   
   
   April 2019
8. ZIMMERMANN FM, De Bruyne B, Pijls NHJ, Desai M, et al
   A protocol update of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial: A comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with
   Am Heart J. 2019;214:156-157.
   PubMed     Text format    
   
   
   
9. QINTAR M, Hirai T, Arnold SV, Sheehy J, et al
   De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status.
   Am Heart J. 2019;214:1-8.
   PubMed     Text format     Abstract available
   
   
   
10. VAN DEN BERG MJ, van der Graaf Y, Deckers JW, de Kanter W, et al
    Smoking cessation and risk of recurrent cardiovascular events and mortality after a first manifestation of arterial disease.
    Am Heart J. 2019;213:112-122.
    PubMed     Text format     Abstract available
    
    
    
11. AKERBLOM A, Wojdyla DM, Wallentin L, James SK, et al
    Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
    Am Heart J. 2019;213:57-65.
    PubMed     Text format     Abstract available
    
    
    
12. GUTIERREZ JA, Bhatt DL, Banerjee S, Glorioso TJ, et al
    Risk of obstructive coronary artery disease and major adverse cardiac events in patients with noncoronary atherosclerosis: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program.
    Am Heart J. 2019;213:47-56.
    PubMed     Text format     Abstract available
    
    
    
13. SULLIVAN LT 2ND, Mulder H, Chiswell K, Shaw LK, et al
    Racial differences in long-term outcomes among black and white patients with drug-eluting stents.
    Am Heart J. 2019;214:46-53.
    PubMed     Text format     Abstract available
    
    
    
14. DECKER PA, Larson NB, Bell EJ, Pankow JS, et al
    Increased hepatocyte growth factor levels over 2 years are associated with coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA).
    Am Heart J. 2019;213:30-34.
    PubMed     Text format     Abstract available
    
    
    
15. VAN ZANDVOORT LJC, Masdjedi K, Tovar Forero MN, Lenzen MJ, et al
    Fractional flow reserve guided percutaneous coronary intervention optimization directed by high-definition intravascular ultrasound versus standard of care: Rationale and study design of the prospective randomized FFR-REACT trial.
    Am Heart J. 2019;213:66-72.
    PubMed     Text format     Abstract available
    
    
    
16. VROEGINDEWEY MM, van den Berg VJ, Bouwens E, Akkerhuis KM, et al
    Temporal evolution of myeloperoxidase and galectin 3 during 1 year after acute coronary syndrome admission.
    Am Heart J. 2019 Apr 6. pii: S0002-8703(19)30052.
    PubMed     Text format     Abstract available
    
    
    
17. HSU S
    Response to the letter to the editor regarding the results of the retrospective study "Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock" published in the American Heart Journal.
    Am Heart J. 2019 Apr 6. pii: S0002-8703(19)30067.
    PubMed     Text format    
    
    
    March 2019
18. SACCO A, Morici N, Oliva F
    Letter to the editor regarding the results of the retrospective study "Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock" published in the American Heart Journal.
    Am Heart J. 2019 Mar 23. pii: S0002-8703(19)30056.
    PubMed     Text format    
    
    
    
19. JENSEN LO, Maeng M, Raungaard B, Engstrom T, et al
    Comparison of the polymer-free biolimus-coated BioFreedom stent with the thin-strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: Rationale and design of the randomize
    Am Heart J. 2019;213:1-7.
    PubMed     Text format     Abstract available
    
    
    
20. XING Y, Liu J, Hao Y, Liu J, et al
    Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: Findings from the Improving Care for Cardiovascular Disease in China (CC
    Am Heart J. 2019;212:120-128.
    PubMed     Text format     Abstract available
    
    
    
21. PUMILL CA, Bush CG, Greiner MA, Hall ME, et al
    Neck circumference and cardiovascular outcomes: Insights from the Jackson Heart Study.
    Am Heart J. 2019;212:72-79.
    PubMed     Text format     Abstract available
    
    
    
22. KIM C, Hong SJ, Shin DH, Kim BK, et al
    Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design.
    Am Heart J. 2019;212:45-52.
    PubMed     Text format     Abstract available
    
    
    
23. ANGRAAL S, Gupta A, Khera R, Nasir K, et al
    Association of access to exercise opportunities and cardiovascular mortality.
    Am Heart J. 2019;212:152-156.
    PubMed     Text format     Abstract available
    
    
    
24. YUDI MB, Clark DJ, Farouque O, Andrianopoulos N, et al
    Trends and predictors of recurrent acute coronary syndrome hospitalizations and unplanned revascularization after index acute myocardial infarction treated with percutaneous coronary intervention.
    Am Heart J. 2019;212:134-143.
    PubMed     Text format     Abstract available
    
    
    
25. HOFFMANN U, Lu MT, Olalere D, Adami EC, et al
    Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.
    Am Heart J. 2019;212:1-12.
    PubMed     Text format     Abstract available
    
    
    
26. YANG N, Liu J, Liu J, Hao Y, et al
    Performance on management strategies with Class I Recommendation and A Level of Evidence among hospitalized patients with non-ST-segment elevation acute coronary syndrome in China: Findings from the Improving Care for Cardiovascular Disease in China-A
    Am Heart J. 2019;212:80-90.
    PubMed     Text format     Abstract available
    
    
    
27. LIP GYH, Mauri L, Montalescot G, Ozkor M, et al
    Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
    Am Heart J. 2019;212:13-22.
    PubMed     Text format     Abstract available
    
    
    February 2019
28. BULLUCK H, Frohlich GM, Nicholas JM, Mohdnazri S, et al
    Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial.
    Am Heart J. 2019;211:60-67.
    PubMed     Text format     Abstract available
    
    
    
29. FINN MT, Redfors B, Karmpaliotis D, Kirtane AJ, et al
    Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study.
    Am Heart J. 2019;211:68-76.
    PubMed     Text format     Abstract available
    
    
    
30. TANG X, Zhang D, He L, Wu N, et al
    Performance of atherosclerotic cardiovascular risk prediction models in a rural Northern Chinese population: Results from the Fangshan Cohort Study.
    Am Heart J. 2019;211:34-44.
    PubMed     Text format     Abstract available
    
    
    January 2019
31. BLAKE SR, Shahzad A, Aggarwal SK, Kumar A, et al
    Radial versus femoral vascular access in ST-elevation myocardial infarction: Are the results of femoral operators unfairly represented in observational research?
    Am Heart J. 2019;210:81-87.
    PubMed     Text format     Abstract available
    
    
    
32. HERTZ JT, Madut DB, Tesha RA, William G, et al
    Knowledge of myocardial infarction symptoms and perceptions of self-risk in Tanzania.
    Am Heart J. 2019;210:69-74.
    PubMed     Text format     Abstract available
    
    
    
33. FERRARI R, Ford I, Fox K, Marzilli M, et al
    A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline character
    Am Heart J. 2019;210:98-107.
    PubMed     Text format     Abstract available
    
    
    
34. KOSMIDOU I, Redfors B, Chen S, Crowley A, et al
    C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial.
    Am Heart J. 2019;210:49-57.
    PubMed     Text format     Abstract available
    
    
    
35. YEBYO HG, Aschmann HE, Kaufmann M, Puhan MA, et al
    Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
    Am Heart J. 2019;210:18-28.
    PubMed     Text format     Abstract available
    
    
    December 2018
36. DESCH S, Freund A, Graf T, Fichtlscherer S, et al
    Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation: Design and rationale of the TOMAHAWK trial.
    Am Heart J. 2018;209:20-28.
    PubMed     Text format     Abstract available
    
    
    
37. IBRAHIM NE, McCarthy CP, Shrestha S, Lyass A, et al
    Blood kidney injury molecule-1 predicts short and longer term kidney outcomes in patients undergoing diagnostic coronary and/or peripheral angiography-Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study.
    Am Heart J. 2018;209:36-46.
    PubMed     Text format     Abstract available
    
    
    
38. WANG X, Tian M, Zheng Z, Gao H, et al
    Rationale and design of a multicenter randomized trial to compare the graft patency between no-touch vein harvesting technique and conventional approach in coronary artery bypass graft surgery.
    Am Heart J. 2018;210:75-80.
    PubMed     Text format     Abstract available
    
    
    
39. FORDYCE CB, Chen AY, Wang TY, Lucas J, et al
    Patterns of use of targeted temperature management for acute myocardial infarction patients following out-of-hospital cardiac arrest: Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2018;206:131-133.
    PubMed     Text format     Abstract available
    
    
    November 2018
40. GIBSON CM, Kerneis M, Yee MK, Daaboul Y, et al
    The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
    Am Heart J. 2018;208:81-90.
    PubMed     Text format     Abstract available
    
    
    
41. DOLL JA, Hellkamp AS, Thomas L, Fonarow GC, et al
    The association of pre- and posthospital medication adherence in myocardial infarction patients.
    Am Heart J. 2018;208:74-80.
    PubMed     Text format     Abstract available
    
    
    
42. HEAD T, Henn L, Andreev VP, Herderick EE, et al
    Accelerated coronary atherosclerosis not explained by traditional risk factors in 13% of young individuals.
    Am Heart J. 2018;208:47-54.
    PubMed     Text format     Abstract available
    
    
    
43. PAGIDIPATI NJ, Coles A, Hemal K, Lee KL, et al
    Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial.
    Am Heart J. 2018;208:28-36.
    PubMed     Text format     Abstract available
    
    
    
44. POLCWIARTEK C, Behrndtz P, Andersen AH, Bregendahl M, et al
    Attitudes and considerations of patients with ST-elevation myocardial infarction toward participation in randomized clinical trials.
    Am Heart J. 2018;208:21-27.
    PubMed     Text format    
    
    
    
45. HELD C, White HD, Stewart RAH, Davies R, et al
    Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
    Am Heart J. 2018;208:65-73.
    PubMed     Text format     Abstract available
    
    
    
46. TRAN HV, Ash AS, Gore JM, Darling CE, et al
    Twenty-five year trends (1986-2011) in hospital incidence and case-fatality rates of ventricular tachycardia and ventricular fibrillation complicating acute myocardial infarction.
    Am Heart J. 2018;208:1-10.
    PubMed     Text format     Abstract available
    
    
    October 2018
47. LAMBRAKIS K, French JK, Scott IA, Briffa T, et al
    The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design.
    Am Heart J. 2018;208:11-20.
    PubMed     Text format     Abstract available
    
    
    
48. MUNKHAUGEN J, Ruddox V, Halvorsen S, Dammen T, et al
    BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study.
    Am Heart J. 2018;208:37-46.
    PubMed     Text format     Abstract available
    
    
    
49. MACHLINE-CARRION MJ, Soares RM, Damiani LP, Campos VB, et al
    Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial.
    Am Heart J. 2018;207:40-48.
    PubMed     Text format     Abstract available
    
    
    
50. PAGIDIPATI NJ, Mudrick DW, Chiswell K, Brucker A, et al
    Sex differences in long-term outcomes of patients across the spectrum of coronary artery disease.
    Am Heart J. 2018;206:51-60.
    PubMed     Text format     Abstract available
    
    
    September 2018
51. PRADHAN AD, Paynter NP, Everett BM, Glynn RJ, et al
    Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
    Am Heart J. 2018;206:80-93.
    PubMed     Text format     Abstract available
    
    
    
52. GUEDENEY P, Baber U, Claessen B, Aquino M, et al
    Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry.
    Am Heart J. 2018;207:10-18.
    PubMed     Text format     Abstract available
    
    
    
53. HARRISON RW, Radhakrishnan V, Allen JC Jr, Lam PS, et al
    The East-West late lumen loss study: Comparison of angiographic late lumen loss between Eastern and Western drug-eluting stent study cohorts.
    Am Heart J. 2018;206:61-71.
    PubMed     Text format     Abstract available
    
    
    
54. CANNON CP, McGuire DK, Pratley R, Dagogo-Jack S, et al
    Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
    Am Heart J. 2018;206:11-23.
    PubMed     Text format     Abstract available
    
    
    August 2018
55. ELGENDY IY, Mansoor H, Li Q, Guo Y, et al
    Long-term mortality and estimated functional capacity among women with symptoms of ischemic heart disease: From the NHLBI-sponsored Women's Ischemia Syndrome Evaluation.
    Am Heart J. 2018 Aug 30. pii: S0002-8703(18)30252.
    PubMed     Text format     Abstract available
    
    
    
56. LEE J, Nakanishi R, Li D, Shaikh K, et al
    Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis.
    Am Heart J. 2018 Aug 24. pii: S0002-8703(18)30249.
    PubMed     Text format     Abstract available
    
    
    
57. ALFONSO F, Cuesta J, Garcia-Guimaraes M, Gonzalez-Barthol E, et al
    Treatment of patients with restenosis of drug-eluting stents.
    Am Heart J. 2018 Aug 24. pii: S0002-8703(18)30250.
    PubMed     Text format    
    
    
    
58. KANG DY, Wong YTA, Park DW, Park SJ, et al
    The authors reply: Treatment of patients with restenosis of drug-eluting stents.
    Am Heart J. 2018 Aug 23. pii: S0002-8703(18)30251.
    PubMed     Text format    
    
    
    
59. MAURI L, Kirtane AJ, Windecker S, Yeh RW, et al
    Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
    Am Heart J. 2018;205:110-117.
    PubMed     Text format     Abstract available
    
    
    
60. EINDHOVEN DC, Wu HW, Kremer SWF, van Erkelens JA, et al
    Mortality differences in acute myocardial infarction patients in the Netherlands: The weekend-effect.
    Am Heart J. 2018;205:70-76.
    PubMed     Text format    
    
    
    
61. CHUNG CJ, Kirtane AJ, Zhang Y, Witzenbichler B, et al
    Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents.
    Am Heart J. 2018;205:77-86.
    PubMed     Text format     Abstract available
    
    
    
62. LAURSEN PN, Holmvang L, Lonborg J, Kober L, et al
    Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study.
    Am Heart J. 2018;204:128-138.
    PubMed     Text format     Abstract available
    
    
    
63. MACK MJ, Abraham WT, Lindenfeld J, Bolling SF, et al
    Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial.
    Am Heart J. 2018;205:1-11.
    PubMed     Text format     Abstract available
    
    
    July 2018
64. BURGESS SN, French JK, Nguyen TL, Leung M, et al
    The impact of incomplete revascularization on early and late outcomes in ST-elevation myocardial infarction.
    Am Heart J. 2018;205:31-41.
    PubMed     Text format     Abstract available
    
    
    
65. PAGIDIPATI NJ, Hellkamp AS, Sharma PP, Wang TY, et al
    High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States.
    Am Heart J. 2018;204:151-155.
    PubMed     Text format     Abstract available
    
    
    
66. STEVENS ER, Farrell D, Jumkhawala SA, Ladapo JA, et al
    Quality of health economic evaluations for the ACC/AHA stable ischemic heart disease practice guideline: A systematic review.
    Am Heart J. 2018;204:17-33.
    PubMed     Text format     Abstract available
    
    
    
67. GIBBONS RJ, Weintraub WS, Brindis RG
    Moving from volume to value for revascularization in stable ischemic heart disease: A review.
    Am Heart J. 2018 Jul 10. pii: S0002-8703(18)30108.
    PubMed     Text format     Abstract available
    
    
    
68. HUGELSHOFER S, Roffi M, Witassek F, Eberli FR, et al
    Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention.
    Am Heart J. 2018;204:34-42.
    PubMed     Text format     Abstract available
    
    
    
69. GUALANDRO DM, Puelacher C, LuratiBuse G, Lampart A, et al
    Comparison of high-sensitivity cardiac troponin I and T for the prediction of cardiac complications after non-cardiac surgery.
    Am Heart J. 2018;203:67-73.
    PubMed     Text format     Abstract available
    
    
    
70. GNANENTHIRAN SR, Yiannikas J, Lowe HC, Brieger D, et al
    Aspirin hypersensitivity in patients with coronary artery disease: linking pathophysiology to clinical practice.
    Am Heart J. 2018;203:74-81.
    PubMed     Text format     Abstract available
    
    
    
71. RYMER JA, Tempelhof MW, Clare RM, Pieper KS, et al
    Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction.
    Am Heart J. 2018;201:103-110.
    PubMed     Text format     Abstract available
    
    
    
72. VENETSANOS D, Lawesson SS, James S, Koul S, et al
    Bivalirudin versus heparin with primary percutaneous coronary intervention.
    Am Heart J. 2018;201:9-16.
    PubMed     Text format     Abstract available
    
    
    
73. INOHARA T, Pieper K, Wojdyla DM, Patel MR, et al
    Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome.
    Am Heart J. 2018;201:25-32.
    PubMed     Text format     Abstract available
    
    
    June 2018
74. XU H, Faxen J, Szummer K, Trevisan M, et al
    Dyskalemias and adverse events associated with discharge potassium in acute myocardial infarction.
    Am Heart J. 2018;205:53-62.
    PubMed     Text format     Abstract available
    
    
    
75. CHI G, Kerneis M, Kalayci A, Liu Y, et al
    Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
    Am Heart J. 2018;203:17-24.
    PubMed     Text format     Abstract available
    
    
    
76. PAOLI G, Notarangelo MF, Mattioli M, La Sala R, et al
    ALLiance for sEcondary PREvention after an acute coronary syndrome. The ALLEPRE trial: A multicenter fully nurse-coordinated intensive intervention program.
    Am Heart J. 2018;203:12-16.
    PubMed     Text format    
    
    
    
77. GREEN JB, Hernandez AF, D'Agostino RB, Granger CB, et al
    Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.
    Am Heart J. 2018;203:30-38.
    PubMed     Text format     Abstract available
    
    
    
78. ATZEMA CL, Dorian P, Fang J, Tu JV, et al
    A clinical decision instrument to predict 30-day death and cardiovascular hospitalizations after an emergency department visit for atrial fibrillation: The Atrial Fibrillation in the Emergency Room, Part 2 (AFTER2) study.
    Am Heart J. 2018;203:85-92.
    PubMed     Text format     Abstract available
    
    
    
79. HJORT M, Lindahl B, Baron T, Jernberg T, et al
    Prognosis in relation to high-sensitivity cardiac troponin T levels in patients with myocardial infarction and non-obstructive coronary arteries.
    Am Heart J. 2018;200:60-66.
    PubMed     Text format     Abstract available
    
    
    
80. ISRAR MZ, Heaney LM, Ng LL, Suzuki T, et al
    B-type natriuretic peptide molecular forms for risk stratification and prediction of outcome after acute myocardial infarction.
    Am Heart J. 2018;200:37-43.
    PubMed     Text format     Abstract available
    
    
    
81. CAPLICE NM, DeVoe MC, Choi J, Dahly D, et al
    Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI).
    Am Heart J. 2018;200:110-117.
    PubMed     Text format     Abstract available
    
    
    
82. CARSON JL, Stanworth SJ, Alexander JH, Roubinian N, et al
    Clinical trials evaluating red blood cell transfusion thresholds: An updated systematic review and with additional focus on patients with cardiovascular disease.
    Am Heart J. 2018;200:96-101.
    PubMed     Text format     Abstract available
    
    
    
83. ELFWEN L, Lagedal R, James S, Jonsson M, et al
    Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG-Short- and long-term survival.
    Am Heart J. 2018;200:90-95.
    PubMed     Text format     Abstract available
    
    
    
84. WIVIOTT SD, Raz I, Bonaca MP, Mosenzon O, et al
    The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
    Am Heart J. 2018;200:83-89.
    PubMed     Text format     Abstract available
    
    
    
85. LATTUCA B, Barber-Chamoux N, Alos B, Sfaxi A, et al
    Impact of video on the understanding and satisfaction of patients receiving informed consent before elective inpatient coronary angiography: A randomized trial.
    Am Heart J. 2018;200:67-74.
    PubMed     Text format     Abstract available
    
    
    
86. PASTORI D, Pignatelli P, Cribari F, Carnevale R, et al
    Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation.
    Am Heart J. 2018;200:32-36.
    PubMed     Text format     Abstract available
    
    
    
87. LOPES RD, Vora AN, Liaw D, Granger CB, et al
    An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention:
    Am Heart J. 2018;200:17-23.
    PubMed     Text format     Abstract available
    
    
    May 2018
88. ITSIOPOULOS C, Kucianski T, Mayr HL, van Gaal WJ, et al
    The AUStralian MEDiterranean Diet Heart Trial (AUSMED Heart Trial): A randomized clinical trial in secondary prevention of coronary heart disease in a multiethnic Australian population: Study protocol.
    Am Heart J. 2018;203:4-11.
    PubMed     Text format     Abstract available
    
    
    
89. VARDENY O, Udell JA, Joseph J, Farkouh ME, et al
    High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.
    Am Heart J. 2018;202:97-103.
    PubMed     Text format     Abstract available
    
    
    
90. HOLMEN J, Herlitz J, Axelsson C
    Immediate coronary intervention in prehospital cardiac arrest-Aiming to save lives.
    Am Heart J. 2018 May 22. pii: S0002-8703(18)30158.
    PubMed     Text format    
    
    
    
91. LI S, Blumenthal JA, Shi C, Millican D, et al
    I-CARE randomized clinical trial integrating depression and acute coronary syndrome care in low-resource hospitals in China: Design and rationale.
    Am Heart J. 2018;202:109-115.
    PubMed     Text format     Abstract available
    
    
    
92. JAKOBSEN L, Christiansen EH, Maeng M, Kristensen SD, et al
    Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian
    Am Heart J. 2018;202:49-53.
    PubMed     Text format     Abstract available
    
    
    
93. HSU S, Kambhampati S, Sciortino CM, Russell SD, et al
    Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock.
    Am Heart J. 2018;199:181-191.
    PubMed     Text format     Abstract available
    
    
    
94. WANG A, Wu A, Wojdyla D, Lopes RD, et al
    Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery.
    Am Heart J. 2018;199:150-155.
    PubMed     Text format     Abstract available
    
    
    
95. GIANOS E, Schoenthaler A, Guo Y, Zhong J, et al
    Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial.
    Am Heart J. 2018;199:37-43.
    PubMed     Text format     Abstract available
    
    
    
96. BRINKLEY DM JR, Ho KKL, Drazner MH, Kociol RD, et al
    The prognostic value of the relationship between right atrial and pulmonary capillary wedge pressure in diverse cardiovascular conditions.
    Am Heart J. 2018;199:31-36.
    PubMed     Text format     Abstract available
    
    
    
97. MARWICK TH, Whitmore K, Nicholls SJ, Stanton T, et al
    Rationale and design of a trial to personalize risk assessment in familial coronary artery disease.
    Am Heart J. 2018;199:22-30.
    PubMed     Text format     Abstract available
    
    
    
98. THEODORAKIS MJ, Coleman RL, Feng H, Chan J, et al
    Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.
    Am Heart J. 2018;199:170-175.
    PubMed     Text format    
    
    
    
99. LACHMAN S, Terbraak MS, Limpens J, Jorstad H, et al
    The prognostic value of heart rate recovery in patients with coronary artery disease: A systematic review and meta-analysis.
    Am Heart J. 2018;199:163-169.
    PubMed     Text format     Abstract available
    
    
    
100. GHARACHOLOU SM, Ijioma NN, Lennon RJ, Rihal CS, et al
     Characteristics and long term outcomes of patients with acute coronary syndromes due to culprit left main coronary artery disease treated with percutaneous coronary intervention.
     Am Heart J. 2018;199:156-162.
     PubMed     Text format     Abstract available
     
     
     
101. YAO X, Gersh BJ, Sangaralingham LR, Shah ND, et al
     Risk of cardiovascular events and incident atrial fibrillation in patients without prior atrial fibrillation: Implications for expanding the indications for anticoagulation.
     Am Heart J. 2018;199:137-143.
     PubMed     Text format     Abstract available
     
     
     
102. BOSWORTH HB, Olsen MK, McCant F, Stechuchak KM, et al
     Telemedicine cardiovascular risk reduction in veterans: The CITIES trial.
     Am Heart J. 2018;199:122-129.
     PubMed     Text format     Abstract available
     
     
     
103. KANG J, Koo BK, Hu X, Lee JM, et al
     Comparison of Fractional FLow Reserve And Intravascular ultrasound-guided Intervention Strategy for Clinical OUtcomes in Patients with InteRmediate Stenosis (FLAVOUR): Rationale and design of a randomized clinical trial.
     Am Heart J. 2018;199:7-12.
     PubMed     Text format     Abstract available
     
     
     
104. VETROVEC GW, Anderson M, Schreiber T, Popma J, et al
     The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure.
     Am Heart J. 2018;199:115-121.
     PubMed     Text format     Abstract available
     
     
     April 2018
105. PATEL KK, Arnold SV, Chan PS, Tang Y, et al
     Validation of the Seattle angina questionnaire in women with ischemic heart disease.
     Am Heart J. 2018;201:117-123.
     PubMed     Text format     Abstract available
     
     
     
106. SPRUILL TM, Reynolds HR, Dickson VV, Shallcross AJ, et al
     Telephone-based mindfulness training to reduce stress in women with myocardial infarction: Rationale and design of a multicenter randomized controlled trial.
     Am Heart J. 2018;202:61-67.
     PubMed     Text format     Abstract available
     
     
     
107. O'NEILL WW, Grines C, Schreiber T, Moses J, et al
     Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device.
     Am Heart J. 2018;202:33-38.
     PubMed     Text format     Abstract available
     
     
     
108. PENNY WF, Henry TD, Watkins MW, Patel AN, et al
     Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial.
     Am Heart J. 2018;201:111-116.
     PubMed     Text format     Abstract available
     
     
     
109. MUHLESTEIN JB, May HT, Galenko O, Knowlton KU, et al
     GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study.
     Am Heart J. 2018;202:27-32.
     PubMed     Text format     Abstract available
     
     
     
110. RAVAL AN, Cook TD, Duckers HJ, Johnston PV, et al
     The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study d
     Am Heart J. 2018;201:141-148.
     PubMed     Text format     Abstract available
     
     
     
111. FORD TJ, Corcoran D, Oldroyd KG, McEntegart M, et al
     Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial.
     Am Heart J. 2018;201:86-94.
     PubMed     Text format     Abstract available
     
     
     
112. RYMER JA, Kaltenbach LA, Anstrom KJ, Fonarow GC, et al
     Hospital evaluation of health literacy and associated outcomes in patients after acute myocardial infarction.
     Am Heart J. 2018;198:97-107.
     PubMed     Text format     Abstract available
     
     
     
113. CHEW DS, Wilton SB, Kavanagh K, Southern DA, et al
     Left ventricular ejection fraction reassessment post-myocardial infarction: Current clinical practice and determinants of adverse remodeling.
     Am Heart J. 2018;198:91-96.
     PubMed     Text format     Abstract available
     
     
     
114. KINNAIRD T, Cockburn J, Gallagher S, Choudhury A, et al
     Temporal changes in radial access use, associates and outcomes in patients undergoing PCI using rotational atherectomy between 2007 and 2014: results from the British Cardiovascular Intervention Society national database.
     Am Heart J. 2018;198:46-54.
     PubMed     Text format     Abstract available
     
     
     
115. CACOUB P, Nahon P, Layese R, Blaise L, et al
     Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.
     Am Heart J. 2018;198:4-17.
     PubMed     Text format     Abstract available
     
     
     
116. BISHAWI M, Hattler B, Almassi GH, Spertus JA, et al
     Preoperative factors associated with worsening in health-related quality of life following coronary artery bypass grafting in the Randomized On/Off Bypass (ROOBY) trial.
     Am Heart J. 2018;198:33-38.
     PubMed     Text format     Abstract available
     
     
     
117. AL RIFAI M, Greenland P, Blaha MJ, Michos ED, et al
     Factors of health in the protection against death and cardiovascular disease among adults with subclinical atherosclerosis.
     Am Heart J. 2018;198:180-188.
     PubMed     Text format     Abstract available
     
     
     
118. NAVAR AM, Pencina MJ, Mulder H, Elias P, et al
     Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles.
     Am Heart J. 2018;198:18-24.
     PubMed     Text format     Abstract available
     
     
     
119. TOMASELLI G, Roach WH, Pina IL, Oster ME, et al
     Government continues to have an important role in promoting cardiovascular health.
     Am Heart J. 2018;198:160-165.
     PubMed     Text format    
     
     
     
120. BOWMAN L, Mafham M, Stevens W, Haynes R, et al
     ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes.
     Am Heart J. 2018;198:135-144.
     PubMed     Text format     Abstract available
     
     
     
121. BATCHELOR W, Dahya V, McGee D, Katopodis J, et al
     Ultrahigh-resolution ultrasound characterization of access site trauma and intimal hyperplasia following use of a 7F sheathless guide versus 6F sheath/guide combination for transradial artery PCI: Results of the PRAGMATIC trial.
     Am Heart J. 2018;198:75-83.
     PubMed     Text format     Abstract available
     
     
     
122. VAN DER HEIJDEN LC, Kok MM, Zocca P, Jessurun GAJ, et al
     Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial.
     Am Heart J. 2018;198:25-32.
     PubMed     Text format     Abstract available
     
     
     
123. BERGMEIJER TO, Reny JL, Pakyz RE, Gong L, et al
     Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).
     Am Heart J. 2018;198:152-159.
     PubMed     Text format     Abstract available
     
     
     
124. BERWANGER O, de Barros E Silva PGM, Dall Orto FTC, de Andrade PB, et al
     Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial.
     Am Heart J. 2018;198:129-134.
     PubMed     Text format     Abstract available
     
     
     March 2018
125. BOHULA EA, Scirica BM, Fanola C, Inzucchi SE, et al
     Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
     Am Heart J. 2018;202:39-48.
     PubMed     Text format     Abstract available
     
     
     
126. BERWANGER O, Nicolau JC, Carvalho AC, Jiang L, et al
     Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial.
     Am Heart J. 2018;202:89-96.
     PubMed     Text format     Abstract available
     
     
     
127. LOOP MS, McClure LA, Levitan EB, Al-Hamdan MZ, et al
     Fine particulate matter and incident coronary heart disease in the REGARDS cohort.
     Am Heart J. 2018;197:94-102.
     PubMed     Text format     Abstract available
     
     
     
128. SHAVADIA JS, French W, Hellkamp AS, Thomas L, et al
     Comprehensive electrocardiogram-to-device time for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: A report from the American Heart Association mission: Lifeline program.
     Am Heart J. 2018;197:9-17.
     PubMed     Text format     Abstract available
     
     
     
129. HAYS AG, Iantorno M, Schar M, Lai S, et al
     The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: A phase 4 randomized, placebo-controlled, double-blind, crossover trial.
     Am Heart J. 2018;197:85-93.
     PubMed     Text format     Abstract available
     
     
     
130. SONG YB, Oh SK, Oh JH, Im ES, et al
     Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
     Am Heart J. 2018;197:77-84.
     PubMed     Text format     Abstract available
     
     
     
131. EGGERS KM, Jernberg T, Lindahl B
     High-sensitivity cardiac troponin T, left ventricular function, and outcome in non-ST elevation acute coronary syndrome.
     Am Heart J. 2018;197:70-76.
     PubMed     Text format     Abstract available
     
     
     
132. LAGEDAL R, Elfwen L, James S, Oldgren J, et al
     Design of DISCO-Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study.
     Am Heart J. 2018;197:53-61.
     PubMed     Text format     Abstract available
     
     
     
133. WONG YTA, Kang DY, Lee JB, Rha SW, et al
     Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial.
     Am Heart J. 2018;197:35-42.
     PubMed     Text format     Abstract available
     
     
     
134. REDFORS B, Genereux P, Witzenbichler B, Maehara A, et al
     Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.
     Am Heart J. 2018;197:142-149.
     PubMed     Text format     Abstract available
     
     
     
135. KOPIN D, Jones WS, Sherwood MW, Wojdyla DM, et al
     Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
     Am Heart J. 2018;197:133-141.
     PubMed     Text format     Abstract available
     
     
     
136. HWANG D, Park KW, Lee JM, Rhee TM, et al
     Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease.
     Am Heart J. 2018;197:103-112.
     PubMed     Text format     Abstract available
     
     
     
137. SHERWOOD MW, Lopes RD, Sun JL, Liaw D, et al
     Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial.
     Am Heart J. 2018;197:1-8.
     PubMed     Text format     Abstract available
     
     
     
138. CZARNY MJ, Miller JM, Naiman DQ, Hwang CW, et al
     Nonprimary PCI at hospitals without cardiac surgery on-site: Consistent outcomes for all?
     Am Heart J. 2018;197:18-26.
     PubMed     Text format     Abstract available
     
     
     February 2018
139. LENG WX, Yang J, Li W, Wang Y, et al
     Rationale and design of the DEAR-OLD trial: Randomized evaluation of routinely Deferred versus EARly invasive strategy in elderly patients of 75 years or OLDer with non-ST-elevation myocardial infarction.
     Am Heart J. 2018;196:65-73.
     PubMed     Text format     Abstract available
     
     
     
140. BAGAI A, Goodman SG, Cantor WJ, Vicaut E, et al
     Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study.
     Am Heart J. 2018;196:56-64.
     PubMed     Text format     Abstract available
     
     
     
141. GUIMARAES PO, Leonardi S, Huang Z, Wallentin L, et al
     Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
     Am Heart J. 2018;196:28-35.
     PubMed     Text format     Abstract available
     
     
     
142. KILIC S, Fabris E, Van't Hof AWJ, Hamm CW, et al
     Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction: Findings from the ATLANTIC trial.
     Am Heart J. 2018;196:1-8.
     PubMed     Text format     Abstract available
     
     
     
143. DUPRE ME, Xu H, Granger BB, Lynch SM, et al
     Access to routine care and risks for 30-day readmission in patients with cardiovascular disease.
     Am Heart J. 2018;196:9-17.
     PubMed     Text format     Abstract available
     
     
     
144. MCCARTHY CP, McEvoy JW, Januzzi JL Jr.
     Biomarkers in stable coronary artery disease.
     Am Heart J. 2018;196:82-96.
     PubMed     Text format     Abstract available
     
     
     
145. ANYANWAGU U, Mamza J, Donnelly R, Idris I, et al
     Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.
     Am Heart J. 2018;196:18-27.
     PubMed     Text format     Abstract available
     
     
     
146. KHAZANIE P, Al-Khatib SM, Wang TY, Crowley MJ, et al
     Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs.
     Am Heart J. 2018;196:170-177.
     PubMed     Text format     Abstract available
     
     
     
147. CROWLEY MJ, Al-Khatib SM, Wang TY, Khazanie P, et al
     How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?
     Am Heart J. 2018;196:163-169.
     PubMed     Text format     Abstract available
     
     
     
148. VRANCKX P, Lewalter T, Valgimigli M, Tijssen JG, et al
     Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial
     Am Heart J. 2018;196:105-112.
     PubMed     Text format     Abstract available
     
     
     
149. LAURIDSEN KG, Schmidt AS, Adelborg K, Bach L, et al
     Effects of hyperoxia on myocardial injury following cardioversion-A randomized clinical trial.
     Am Heart J. 2018;196:97-104.
     PubMed     Text format     Abstract available
     
     
     
150. SCIAHBASI A, Frigoli E, Sarandrea A, Calabro P, et al
     Determinants of radiation dose during right transradial access: Insights from the RAD-MATRIX study.
     Am Heart J. 2018;196:113-118.
     PubMed     Text format     Abstract available
     
     
     January 2018
151. AFANA M, Gurm HS, Seth M, Frazier KM, et al
     Primary percutaneous coronary intervention at centers with and without on-site surgical support: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
     Am Heart J. 2018;195:99-107.
     PubMed     Text format     Abstract available
     
     
     
152. TARANTINI G, Ueshima D, D'Amico G, Masiero G, et al
     Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis.
     Am Heart J. 2018;195:78-85.
     PubMed     Text format     Abstract available
     
     
     
153. ISSA OM, Roberts R, Mark DB, Boineau R, et al
     Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT).
     Am Heart J. 2018;195:70-77.
     PubMed     Text format     Abstract available
     
     
     
154. BOSSARD M, Binbraik Y, Beygui F, Pitt B, et al
     Mineralocorticoid receptor antagonists in patients with acute myocardial infarction - A systematic review and meta-analysis of randomized trials.
     Am Heart J. 2018;195:60-69.
     PubMed     Text format     Abstract available
     
     
     
155. LIU E, Hsueh L, Kim H, Vidovich MI, et al
     Global geographical variation in patient characteristics in percutaneous coronary intervention clinical trials: A systematic review and meta-analysis.
     Am Heart J. 2018;195:39-49.
     PubMed     Text format     Abstract available
     
     
     
156. HESS PL, Kennedy K, Cowherd M, Virani SS, et al
     Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project.
     Am Heart J. 2018;195:151-152.
     PubMed     Text format    
     
     
     
157. VEMULAPALLI S, Holmes DR Jr, Dai D, Matsouaka R, et al
     Valve hemodynamic deterioration and cardiovascular outcomes in TAVR: A report from the STS/ACC TVT Registry.
     Am Heart J. 2018;195:1-13.
     PubMed     Text format     Abstract available
     
     
     December 2017
158. ILIESCU CA, Cilingiroglu M, Giza DE, Rosales O, et al
     "Bringing on the light" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry).
     Am Heart J. 2017;194:83-91.
     PubMed     Text format     Abstract available
     
     
     
159. QADERDAN K, Vos GA, McAndrew T, Steg PG, et al
     Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials.
     Am Heart J. 2017;194:73-82.
     PubMed     Text format     Abstract available
     
     
     
160. INOHARA T, Numasawa Y, Higashi T, Ueda I, et al
     Predictors of high cost after percutaneous coronary intervention: A review from Japanese multicenter registry overviewing the influence of procedural complications.
     Am Heart J. 2017;194:61-72.
     PubMed     Text format     Abstract available
     
     
     
161. DESAI NR, Kennedy KF, Cohen DJ, Connolly T, et al
     Contemporary risk model for inhospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry(R)-Get With The Guidelines (GWTG)(R).
     Am Heart J. 2017;194:16-24.
     PubMed     Text format     Abstract available
     
     
     
162. HIRJI SA, Stevens SR, Shaw LK, Campbell EC, et al
     Predicting risk of cardiac events among ST-segment elevation myocardial infarction patients with conservatively managed non-infarct-related artery coronary artery disease: An analysis of the Duke Databank for Cardiovascular Disease.
     Am Heart J. 2017;194:116-124.
     PubMed     Text format     Abstract available
     
     
     
163. GO AS, Fan D, Sung SH, Inveiss AI, et al
     Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study.
     Am Heart J. 2017;194:25-38.
     PubMed     Text format     Abstract available
     
     
     November 2017
164. MUSTO C, De Felice F, Rigattieri S, Chin D, et al
     Instantaneous wave-free ratio and fractional flow reserve for the assessment of nonculprit lesions during the index procedure in patients with ST-segment elevation myocardial infarction: The WAVE study.
     Am Heart J. 2017;193:63-69.
     PubMed     Text format     Abstract available
     
     
     
165. RUSSO JJ, Goodman SG, Cantor WJ, Ko DT, et al
     Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis.
     Am Heart J. 2017;193:46-54.
     PubMed     Text format     Abstract available
     
     
     
166. AKINTOYE E, Briasoulis A, Afonso L
     Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification.
     Am Heart J. 2017;193:95-103.
     PubMed     Text format     Abstract available
     
     
     
167. LEE PH, Lee JY, Lee CW, Han S, et al
     Long-term outcomes of bypass grafting versus drug-eluting stenting for left main coronary artery disease: Results from the IRIS-MAIN registry.
     Am Heart J. 2017;193:76-83.
     PubMed     Text format     Abstract available
     
     
     
168. DOROS G, Massaro JM, Kandzari DE, Waksman R, et al
     Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach.
     Am Heart J. 2017;193:35-45.
     PubMed     Text format     Abstract available
     
     
     
169. CHIANG MH, Wu HH, Shih CJ, Chen YT, et al
     Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients.
     Am Heart J. 2017;193:1-7.
     PubMed     Text format     Abstract available
     
     
     
170. SHADDY R, Canter C, Halnon N, Kochilas L, et al
     Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
     Am Heart J. 2017;193:23-34.
     PubMed     Text format     Abstract available
     
     
     October 2017
171. WAKSMAN R, Torguson R, Spad MA, Garcia-Garcia H, et al
     The Lipid-Rich Plaque Study of vulnerable plaques and vulnerable patients: Study design and rationale.
     Am Heart J. 2017;192:98-104.
     PubMed     Text format     Abstract available
     
     
     
172. JESSEE R, Peart E, Beineke P, Rosenberg S, et al
     Rheumatoid arthritis complicates noninvasive whole blood gene expression testing for coronary artery disease.
     Am Heart J. 2017;192:13-18.
     PubMed     Text format     Abstract available
     
     
     
173. DEHGHANI P, Lavoie A, Lavi S, Crawford JJ, et al
     Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
     Am Heart J. 2017;192:105-112.
     PubMed     Text format     Abstract available
     
     
     
174. ALBERT MA, Durazo EM, Slopen N, Zaslavsky AM, et al
     Cumulative psychological stress and cardiovascular disease risk in middle aged and older women: Rationale, design, and baseline characteristics.
     Am Heart J. 2017;192:1-12.
     PubMed     Text format     Abstract available
     
     
     September 2017
175. WALLERT J, Held C, Madison G, Olsson EM, et al
     Temporal changes in myocardial infarction incidence rates are associated with periods of perceived psychosocial stress: A SWEDEHEART national registry study.
     Am Heart J. 2017;191:12-20.
     PubMed     Text format     Abstract available
     
     
     
176. GUDNADOTTIR GS, Andersen K, Thrainsdottir IS, James SK, et al
     Gender differences in coronary angiography, subsequent interventions, and outcomes among patients with acute coronary syndromes.
     Am Heart J. 2017;191:65-74.
     PubMed     Text format     Abstract available
     
     
     
177. FARB A, Zuckerman BD
     Clinical event adjudication in cardiovascular device trials: An Food and Drug Administration perspective.
     Am Heart J. 2017;191:62-64.
     PubMed     Text format    
     
     
     
178. REN HY, Khera A, de Lemos JA, Ayers CR, et al
     Soluble endothelial cell-selective adhesion molecule and incident cardiovascular events in a multiethnic population.
     Am Heart J. 2017;191:55-61.
     PubMed     Text format     Abstract available
     
     
     
179. KIM Y, Soffler M, Paradise S, Jelani QU, et al
     Depression is associated with recurrent chest pain with or without coronary artery disease: A prospective cohort study in the emergency department.
     Am Heart J. 2017;191:47-54.
     PubMed     Text format     Abstract available
     
     
     
180. WEI J, Mehta PK, Grey E, Garberich RF, et al
     Sex-based differences in quality of care and outcomes in a health system using a standardized STEMI protocol.
     Am Heart J. 2017;191:30-36.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: